A phase Ia first-in-human study of BPB-101, a novel trifunctional antibody targeting the GARP/TGF-β complex and PD-L1, in patients with locally advanced or metastatic solid tumors

Yuxiang Ma, Yufeng Guo, Shuang Deng, Haitao Lan, Suxia Luo, Keqiang Zhang, Qingqing Hu, Tao Fu, Pengxiang Wu, Qiuyue Cao, Luyang Zhao, Li Mao, Lieming Ding, Yan Huang, Yuanyuan Zhao, Yang Zhang, Jinhui Xue, Li Zhang, Hongyun Zhao

Open source

DOI: 10.1186/s13045-026-01867-7
Published: 2026-11-03
Container: Journal of Hematology & Oncology
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s13045-026-01867-7,
  title = {A phase Ia first-in-human study of BPB-101, a novel trifunctional antibody targeting the GARP/TGF-β complex and PD-L1, in patients with locally advanced or metastatic solid tumors},
  author = {Yuxiang Ma and Yufeng Guo and Shuang Deng and Haitao Lan and Suxia Luo and Keqiang Zhang and Qingqing Hu and Tao Fu and Pengxiang Wu and Qiuyue Cao and Luyang Zhao and Li Mao and Lieming Ding and Yan Huang and Yuanyuan Zhao and Yang Zhang and Jinhui Xue and Li Zhang and Hongyun Zhao},
  year = {2026},
  journal = {Journal of Hematology \&amp; Oncology},
  doi = {10.1186/s13045-026-01867-7},
  url = {https://doi.org/10.1186/s13045-026-01867-7}
}

RIS

TY  - JOUR
TI  - A phase Ia first-in-human study of BPB-101, a novel trifunctional antibody targeting the GARP/TGF-β complex and PD-L1, in patients with locally advanced or metastatic solid tumors
AU  - Yuxiang Ma
AU  - Yufeng Guo
AU  - Shuang Deng
AU  - Haitao Lan
AU  - Suxia Luo
AU  - Keqiang Zhang
AU  - Qingqing Hu
AU  - Tao Fu
AU  - Pengxiang Wu
AU  - Qiuyue Cao
AU  - Luyang Zhao
AU  - Li Mao
AU  - Lieming Ding
AU  - Yan Huang
AU  - Yuanyuan Zhao
AU  - Yang Zhang
AU  - Jinhui Xue
AU  - Li Zhang
AU  - Hongyun Zhao
PY  - 2026
JO  - Journal of Hematology &amp; Oncology
DO  - 10.1186/s13045-026-01867-7
UR  - https://doi.org/10.1186/s13045-026-01867-7
ER  -

APA

Ma, Y., Guo, Y., Deng, S., Lan, H., Luo, S., Zhang, K., Hu, Q., Fu, T., Wu, P., Cao, Q., Zhao, L., Mao, L., Ding, L., Huang, Y., Zhao, Y., Zhang, Y., Xue, J., Zhang, L., & Zhao, H. (2026). A phase Ia first-in-human study of BPB-101, a novel trifunctional antibody targeting the GARP/TGF-β complex and PD-L1, in patients with locally advanced or metastatic solid tumors. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-026-01867-7

Source records

crossref · retrieved 2026-11-06T23:04:08.619Z